1Y Close · As of Aug 26, 2026
NeoImmuneTech operates in the Professional Services sector.
Legal name: NeoImmuneTech, Inc.
In fiscal year 2025, NeoImmuneTech (950220) reported revenue of 66,673 KRW, down 46.6% from 124,917 KRW a year earlier.
Operating profit was -18 million KRW and net income was -22 million KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 95.8 billion KRW, with a P/B of 2321.38.
These figures can be verified in the DART filing (receipt no. 20260319001392).
Recent Filings
Corporate Briefing (IR)
투자판단관련주요경영사항 (NTI7 흉선 기능 관련 적응증에 대한)
Material Business Matters (Clinical Trial Results)
Checks
4 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-19 | Corporate Briefing (IR) |
| 2026-08-19 | 투자판단관련주요경영사항 (NTI7 흉선 기능 관련 적응증에 대한) |
| 2026-08-18 | Material Business Matters (Clinical Trial Results) |
| 2026-08-12 | Semi-Annual Report (2026.06) |